검색어 : 통합검색[Cancer drug discovery and development]
총 10,586건 중 1,000건 출력
, 5/100 페이지
-
41
- Anti-cancer drug discovery and development : Bcl-2 family small molecule inhibitors
- Liu, Qiang; Wang, Hong-Gang; Department of Pharmacology and Penn State Hershey Cancer Institute; The Pennsylvania University College of Medicine; Hershey, PA USA; Department of Pharmacology and Penn State Hershey Cancer Institute; The Pennsylvania University College of Medicine; Hershey, PA USA; (Communicative & integrative biology, v.5, 2012, pp.557-565)
-
42
- [Front-line drug discovery system for cancer]
- Mizukami, Tamio; ; (癌と化學療法 = Cancer & chemotherapy, v.35, 2008, pp.2293-2300)
-
43
- Utilizing RNA interference to enhance cancer drug discovery
- Iorns, Elizabeth; Lord, Christopher J.; Turner, Nicholas; Ashworth, Alan; The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK.; The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK.; The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK.; The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK.; (Nature reviews. Drug discovery, v.6, 2007, pp.556-568)
-
44
- Surrogate endpoints in cancer drug development
- Sikora, Karol; ; (Drug discovery today, v.7, 2002, pp.951-956)
-
45
- Advances in cancer drug discovery - a British association for cancer research meeting.
- Westwell, Andrew D; ; (IDrugs : the investigational drugs journal, v.11, 2008, pp.783-786)
-
46
- Why is cancer drug discovery so difficult?
- Kamb, Alexander; Wee, Susan; Lengauer, Christoph; Alexander Kamb is at Amgen, 1120 Veterans Boulevard, South San Francisco, California 94010, USA.; Susan Wee and Christoph Lengauer are at the Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.; Susan Wee and Christoph Lengauer are at the Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.; (Nature reviews. Drug discovery, v.6, 2007, pp.115-120)
-
47
- Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone
- Workman, Paul; ; (Cancer detection and prevention, v.26, 2002, pp.405-410)
-
48
- Impact of CRISPR in cancer drug discovery
- Moffat, Jason; Komor, Alexis C.; Lum, Lawrence; Program in Genetics and Genome Biology, The Hospital for Sick Children, Department of Molecular Genetics, University of Toronto, Toronto, Canada.; University of California San Diego, La Jolla, CA,USA.; University of Texas Southwestern Medical Center, Dallas, TX, USA.; (Science, v.386, 2024, pp.378-379)
-
49
- Neoadjuvant Trials in ER<sup>+</sup> Breast Cancer: A Tool for Acceleration of Drug Development and Discovery
- Guerrero-Zotano, Angel L.; Arteaga, Carlos L.; ; (Cancer discovery, v.7, 2017, pp.561-574)
-
50
- Early Drug Discovery and Development of Novel Cancer Therapeutics Targeting DNA Polymerase Eta (POLH)
- Wilson 3rd, David M.; Duncton, Matthew A. J.; Chang, Caleb; Lee Luo, Christie; Georgiadis, Taxiarchis M.; Pellicena, Patricia; Deacon, Ashley M.; Gao, Yang; Das, Debanu; XPose Therapeutics, Inc. , San Carlos, CA , United States; XPose Therapeutics, Inc. , San Carlos, CA , United States; Department of BioSciences, Rice University , Houston, TX , United States; Department of BioSciences, Rice University , Houston, TX , United States; XPose Therapeutics, Inc. , San Carlos, CA , United States; XPose Therapeutics, Inc. , San Carlos, CA , United States; XPose Therapeutics, Inc. , San Carlos, CA , United States; Department of BioSciences, Rice University , Houston, TX , United States; XPose Therapeutics, Inc. , San Carlos, CA , United States; (Frontiers in oncology, v.11, 2021, pp.778925)
QUICK MENU
